Viatris Inc. (VIE:VTRS)

Austria flag Austria · Delayed Price · Currency is EUR
12.41
-0.11 (-0.86%)
Last updated: Apr 27, 2026, 1:00 PM CET
Market Cap14.51B +72.5%
Revenue (ttm)12.18B -3.0%
Net Income-2.99B
EPS-2.56
Shares Outn/a
PE Ration/a
Forward PE5.97
Dividend0.42 (3.36%)
Ex-Dividend DateMar 9, 2026
Volumen/a
Average Volume1
Open12.43
Previous Close12.52
Day's Range12.41 - 12.43
52-Week Range6.87 - 13.87
Betan/a
RSI59.32
Earnings DateMay 7, 2026

About Viatris

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]

Industry Pharmaceutical Preparations
Founded 1961
Employees 30,000
Stock Exchange Vienna Stock Exchange
Ticker Symbol VTRS

Financial Performance

In 2025, Viatris's revenue was $14.30 billion, a decrease of -2.98% compared to the previous year's $14.74 billion. Losses were -$3.51 billion, 454.2% more than in 2024.

Financial numbers in USD Financial Statements

News

Viatris to Report First Quarter 2026 Financial Results on May 7, 2026

PITTSBURGH, April 13, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Compa...

14 days ago - PRNewsWire

Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

PITTSBURGH, April 10, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract and Refra...

17 days ago - PRNewsWire

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

27 days ago - Benzinga

Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

Addresses a Significant Unmet Need in Japan as First and Only Approved Treatment Option for GAD PITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, tod...

5 weeks ago - PRNewsWire

Viatris Transcript: Investor update

A focused transformation has positioned the company for sustainable growth, targeting 5%-6% revenue and 7%-8% EBITDA growth by 2030, with over $11B in capital for deployment. Key drivers include a robust pipeline, disciplined business development, and operational efficiencies.

5 weeks ago - Transcripts

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful Near-Term Launches, Including Fast-Acting Meloxic...

5 weeks ago - PRNewsWire

Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research

Generic drugmaker Viatris has settled a lawsuit brought by the family of Henrietta Lacks, a Maryland woman whose tissue samples were ​used without her permission to develop enduring cells for lucrativ...

6 weeks ago - Reuters

These S&P 500 stocks are falling the hardest on Tuesday

Stocks of gold miners and computer-memory makers were hit especially hard, while Best Buy led the S&P 500 with a gain after its earnings report.

7 weeks ago - Market Watch

AI Is Sliding and Everything Else Has Run Up. Here Are 6 Stocks That Look Like Buys.

It can seem like a nothing-to-buy market. But there are solid stocks out there.

2 months ago - Barrons

Viatris forecasts 2026 profit below estimates on India manufacturing woes

Drugmaker Viatris forecast annual profit below analysts' expectations on Thursday, after a fire at one of its major plants in India disrupted operations.

2 months ago - Reuters

Viatris Earnings Call Transcript: Q4 2025

2025 saw 2% revenue growth and strong pipeline progress, with $14.3B in revenue and $4.2B Adjusted EBITDA. Strategic review identified $650M in cost savings, supporting 2% growth guidance for 2026 and multiple product launches. Over $1B was returned to shareholders.

2 months ago - Transcripts

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

Reports Fourth-Quarter Total Revenues of $ 3.7B and Full-Year 2025 Total Revenues of $ 14.3B Meets or Exceeds 2025 Financial Guidance Across All Key Metrics[1] Returns More Than $1B to Shareholders in...

2 months ago - PRNewsWire

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share an...

2 months ago - PRNewsWire

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

FDA PDUFA Goal Date Set for October 17, 2026 PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administrat...

2 months ago - PRNewsWire

Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026

NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depo...

2 months ago - GlobeNewsWire

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, Febru...

2 months ago - PRNewsWire

Viatris Appoints Matthew J. Maletta as Chief Legal Officer

Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) anno...

2 months ago - PRNewsWire

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today anno...

3 months ago - PRNewsWire

Viatris Transcript: 44th Annual J.P. Morgan Healthcare Conference

Management highlighted strong 2025 execution, robust pipeline progress, and a strategic shift toward sustainable growth starting in 2026. Key launches, business development, and an enterprise-wide review are set to drive mid-single digit revenue growth and operational efficiency.

3 months ago - Transcripts

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing trans...

3 months ago - PRNewsWire

Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration

Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference

3 months ago - GlobeNewsWire

Viatris Provides Pipeline Update on Four Regulatory Milestones

Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR Depot (Octreotide Acetate for Injectable Suspension) U.S. FDA Accepts New Drug Application for Low Dos...

4 months ago - PRNewsWire

Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference

PITTSBURGH , Dec. 17, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference ...

4 months ago - PRNewsWire

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited

Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Compete Restrictions PITTSBURGH , Dec. 6, 2025 /PR...

5 months ago - PRNewsWire

Viatris Transcript: Evercore ISI 8th Annual HealthCONx Conference

Management outlined a strategy focused on reinforcing the base business, driving innovation, and optimizing costs for sustainable growth. Key pipeline assets, including fast-acting meloxicam and late-stage candidates selatogrel and cenerimod, are expected to drive future revenue, with launches and pivotal data readouts anticipated next year.

5 months ago - Transcripts